In a nutshell
This study investigated the effectiveness of dutasteride (Avodart) in the treatment of benign prostatic hyperplasia (BPH).
Some background
Dutasteride, a five-alpha reductase inhibitor (5ARI), reduces prostate size by blocking the effects of the hormone testosterone. Dutasteride is commonly used to treat urinary symptoms associated with BPH.
Methods & findings
This study reviewed recently published evidence to define the harms and benefits of dutasteride treatment. Four trials were included in this meta-analysis (an analysis of data combined from several similar trials). A total of 6460 men received dutasteride, and 6475 received placebo treatment (sham treatment with no medical effect).
Patient reported symptom scores were significantly improved with dutasteride treatment compared to placebo. Measured urine flow rates were also increased with dutasteride treatment. Prostate volume was reduced by an average of 13.86 mL among men receiving dutasteride.
The risk for urinary retention (inability to pass urine, often requiring surgical intervention) was reduced by 65% among men receiving dutasteride.
The major side effect reported with dutasteride was sexual dysfunction (including erectile dysfunction, ejaculation disorders and decreased sexual drive). Sexual dysfunction was reported among 14.8% of men receiving dutasteride (compared to 6% of men receiving a placebo).
The bottom line
This analysis concluded that dutasteride is highly effective in treating BPH symptoms and reducing the size of an enlarged prostate. Dutasteride also reduces the risk of urine retention and the need for surgery, but is related to an increased rate of sexual dysfunction.
Published By :
Urology
Date :
Mar 01, 2014
